| Literature DB >> 22550471 |
Santhosh K Venkatesan1, Vikash Kumar Dubey.
Abstract
Structure-based virtual screening of NCI Diversity set II compounds was performed to indentify novel inhibitor scaffolds of trypanothione reductase (TR) from Leishmania infantum. The top 50 ranked hits were clustered using the AuPoSOM tool. Majority of the top-ranked compounds were Tricyclic. Clustering of hits yielded four major clusters each comprising varying number of subclusters differing in their mode of binding and orientation in the active site. Moreover, for the first time, we report selected alkaloids and dibenzothiazepines as inhibitors of Leishmania infantum TR. The mode of binding observed among the clusters also potentiates the probable in vitro inhibition kinetics and aids in defining key interaction which might contribute to the inhibition of enzymatic reduction of T[S] 2. The method provides scope for automation and integration into the virtual screening process employing docking softwares, for clustering the small molecule inhibitors based upon protein-ligand interactions.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22550471 PMCID: PMC3322522 DOI: 10.1100/2012/963658
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Structure and docking statistics of top 50 ranked structures. C, CL, E, A, and T indicate numbers of clusters, number of conformations within the selected cluster, binding energy of the selected conformation in kcal/mol, number of atoms in the inhibitor, and number of torsions, respectively.
|
|
Figure 1Cluster tree showing four major clusters (Cluster 1, Cluster 2, Cluster 3, and Cluster 4), each cluster signifies a different ligand footprint on the protein-ligand complex. The protein-ligand interactions within the cluster are conserved; they vary between the clusters. The subclusters within a cluster also show similar interaction modes with slight variation in the binding pattern.
Table showing conserved interaction of ligands with active site residues of TR within clusters.
| S. no. | Cluster | Compounds present in the cluster* | Conserved interaction within the cluster (bonding and nonbonding interactions) |
|---|---|---|---|
| 1 | Cluster 1 | SC-1 [Cpd3, Cpd8, Cpd9, Cpd16, Cpd38, Cpd43] | Leu399, Ser14, Glu18, Trp21, Tyr110, Met113, Cys52 |
| SC-2 [Cpd5, Cpd21, Cpd25] | |||
| 2 | Cluster 2 | SC-3[Cpd7, Cpd17, Cpd20, Cpd26, Cpd40, Cpd42] | His461, Leu399, Thr65, Glu466, Pro398, Thr396, Phe396, Pro398 |
| SC-4[Cpd2, Cpd15] | |||
| SC-5[Cpd24, Cpd37, Cpd48] | |||
| SC-6[Cpd6,Cpd23] | |||
| 3 | Cluster 3 | SC-7[Cpd14, Cpd29, Cpd30, Cpd31, Cpd49, Cpd32] | Glu466, Glu467, Thr463, Ser394 |
| 4 | Cluster 4 | SC-8[Cpd10, Cpd44, Cpd50] | Leu399, Pro398, Phe396, |
| SC-9[Cpd12, Cpd19, Cpd27, Cpd28, Cpd33, Cpd34, Cpd36, Cpd46, Cpd47] | Met400, Lys61 | ||
| SC-10[Cpd22, Cpd45] | |||
| SC-11[Cpd1, Cpd4, Cpd11, Cpd13, Cpd18, Cpd39, Cpd41] | |||
| SC-12[Cpd35] |
*[ ] subclusters (SC) within major clusters are separated using [ ].
Figure 2Orientation of inhibitors segregated into four different clusters at the active site of TR. Inhibitors in Cluster 1 (a) position themselves between both the hydrophobic patches of the active site, Cluster 2 (b) bind to the Z site with their side chains orienting themselves towards the negatively charged residues of the active site. In Cluster 3 (c), the ligands primarily bind to the negatively charged residues such as Glu466, Glu467 residues involved in orientation of active site histidine during hydride transfer process, in Cluster 4 (d) comprise of compounds which stack to the Z site, in the vicinity of the active site and they also interact with Lys61 of the substrate-binding site.
Figure 3Compound 16 (a) of cluster 1 traversed between hydrophobic patches formed by Trp21, Met114 and Leu399, Pro492, and Pro398 where later is located in vicinity to the substrate-binding site, it also showed hydrogen bonding potential with Tyr110 of the active site, Tyr110 anchors the substrate to the active site by hydrogen bonding with the spermidine moiety. Compound 48 (b) of Cluster 2 binds to the Z site with hydrogen bonding potentials with His461, active site histidine base, and also with the residues which aid in orientation of substrate towards the active site.
Figure 4Ligplot showing proposed hydrogen bonding and non bonding interaction of Compound 38 (a) and Compound 20 (b) from Cluster 1, Cluster 2, respectively. They bind to the active site with specific interaction pattern representation of each cluster. Compound 38 stacks itself between two hydrophobic patches in the active site, whereas compound 20 is in nonbonding interaction with Z site residues and Glu of active site.
Figure 5Binding Compound 31 (a) at the active site, the compound is lodged at the periphery of the active site, with potential hydrogen bonding interactions with Glu4666 and Glu467 making it a high-affinity interaction. Compound 47 (b) belonging to Cluster 4 binds to the additional hydrophobic patch with side chains extending towards the substrate-binding cleft.
Figure 6Compound 30 (a) of Cluster 3 in hydrogen bonding interaction with Glu466, Glu467, Thr463, Pro398, and Phe396 of the Z site is in hydrophobic contact with the inhibitor. Compound 35 (b) is in hydrophobic interaction with all the Z site residues, and there are other amino acids in non-boding interactions making it a high-affinity binding.